|
Post by magnus123 on May 6, 2020 16:21:29 GMT
|
|
|
Post by JHam on May 6, 2020 17:03:41 GMT
And Franz Walt was just on the Mike Graham talkRadio show. Really great info. Franz says that they are getting major interest from all over the UK and Europe. He also said that they can do 30M tests per year, and can double that amount if needed in the next 18 months: quotientbd.com/news/quotient-ceo-franz-walt-talkradio-mike-graham
|
|
|
Post by iamwhatiam on May 7, 2020 0:52:39 GMT
I've been a long time watcher and member of this site, but it's been a while, like since the OCATA days, since I've posted anything. I always appreciate everyone's views here. So thank you for the site itself Jham, and to all the regular contributors. Quick question regarding the perceived usefulness of Quotient's antibody testing related specifically to COVID-19. If the scientific community is still not sure that people with COVID-19 antibodies have immunity to the disease, then what will be the motivation to pay for antibody testing in the kind of numbers to make this company highly profitable? I understand reasonably well how they will make money, I'm just trying to get a handle on what the demand may be. Certainly if it can be demonstrated conclusively that those with the antibodies are immune then that provides significant motivation for widespread testing, and I would assume Quotient would be a beneficiary of this elevated demand. Thank you for any thoughts you may be able to share or links to more information. Hey iamwhatiam, long time no see. There’s a lot to unpack here from your post. First, the only way to determine whether or not people have immunity is to form a baseline of those who have antibodies. That is what the MosaiQ (QTNT) test does. If having antibodies ultimately proves immunity, then that bodes well for QTNT in relation to COVID-19. If having bodies doesn’t prove immunity then it simply means that antibodies doesn’t give you immunity. Which has nothing to do with QTNT’s technology. Sure, they won’t get a pop from COVID-19, but it is still a validation for their technology. Remember, their core business ultimately targets a $40B market. COVID-19 represents the tip of the stem of the cherry on top of the cake. Although COVID-19 could be worth $300-500M in unexpected revenue, the real value here in my opinion, is that it speeds up the validation process of their core business. Thank you for your response JHam, and for making us aware of this company. I agree there is a considerable market for this technology independent of the COVID-19 issue. For the sake of overcoming this disease I hope a valid link is found between the presence of antibodies and immunity because it could be a major boon to fighting this thing and it would also happen to be great for QTNT. I wish you and the other good folk on here all the best.
|
|
|
Post by JHam on May 7, 2020 2:04:17 GMT
Hey iamwhatiam, long time no see. There’s a lot to unpack here from your post. First, the only way to determine whether or not people have immunity is to form a baseline of those who have antibodies. That is what the MosaiQ (QTNT) test does. If having antibodies ultimately proves immunity, then that bodes well for QTNT in relation to COVID-19. If having bodies doesn’t prove immunity then it simply means that antibodies doesn’t give you immunity. Which has nothing to do with QTNT’s technology. Sure, they won’t get a pop from COVID-19, but it is still a validation for their technology. Remember, their core business ultimately targets a $40B market. COVID-19 represents the tip of the stem of the cherry on top of the cake. Although COVID-19 could be worth $300-500M in unexpected revenue, the real value here in my opinion, is that it speeds up the validation process of their core business. Thank you for your response JHam, and for making us aware of this company. I agree there is a considerable market for this technology independent of the COVID-19 issue. For the sake of overcoming this disease I hope a valid link is found between the presence of antibodies and immunity because it could be a major boon to fighting this thing and it would also happen to be great for QTNT. I wish you and the other good folk on here all the best. No problem. If you have a chance I’d give a quick listen to the radio interview I posted earlier today. At 4:30 the CEO discusses the many ways in which this test is important. As I relistened I noticed him also saying at 5:25, that they are in discussions with a pharma company about using MosaiQ for plasma transfusion. That has the potential to be a major news event.
|
|
|
Post by JHam on May 7, 2020 17:13:00 GMT
Just added at $7.55. Averaged up. Hoping it will be worth it in the long run.
|
|
|
Post by magnus123 on May 7, 2020 17:56:52 GMT
Just added at $7.55. Averaged up. Hoping it will be worth it in the long run. Me too. Nice opportunity. I really hope that the EUA comes soon.
|
|
|
Post by JHam on May 7, 2020 18:01:37 GMT
Just added at $7.55. Averaged up. Hoping it will be worth it in the long run. Me too. Nice opportunity. I really hope that the EUA comes soon. Crossing my fingers that we hear something next week.
|
|
|
Post by Yelk on May 7, 2020 18:25:33 GMT
Nice work with patience entries guys! Best of luck!
|
|
|
Post by iamwhatiam on May 7, 2020 18:59:44 GMT
Anyone else seeing zero volume since 2:11 pm, despite the price fluctuating between $7.52 and $7.69? I bought some at $7.51 at about 2.47 pm but no volume showed up then either?
Please ignore above, the trades turned up eventually.
|
|
|
Post by JHam on May 11, 2020 7:29:53 GMT
BAM! MosaiQ is hVIVO's exclusive COVID-19 test in the UK. Let's hope this gets the ball rolling in EU. www.globenewswire.com/news-release/2020/05/11/2030728/0/en/Quotient-Limited-and-hVIVO-Announce-Partnership-to-Support-Wide-Spread-COVID-19-Antibody-Testing-in-the-UK.htmlQuotient Limited and hVIVO Announce Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UKMay 11, 2020 02:00 ET | Source: Quotient Limited
JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody Microarray will be used by hVIVO to screen for SARS-CoV-2 antibodies (COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO's exclusive supplier of COVID-19 antibody testing equipment, to support COVID-19 antibody testing in the UK.
hVIVO, based in London, UK, is a world leader in the testing of vaccines and antivirals using human challenge study models.
“We are delighted to exclusively partner with Quotient to bring fast and accurate COVID-19 antibody testing to the UK. Open Orphan plc, via our subsidiary hVIVO, has industry leading scientific and laboratory capability and the MosaiQ™ system’s best in class COVID-19 antibody testing performance makes the system a natural addition to our state-of-the-art virology laboratory in London. There is a clear demand for COVID-19 antibody testing and we will be making testing available both as a standalone offering and will also utilize the testing capability to screen volunteers for our industry leading range of human challenge studies to ensure no disruption to our clients,” said Cathal Friel, Executive Chairman, hVIVO, part of Open Orphan plc.
“This collaboration marks a major milestone for our company, and we are proud to collaborate with an industry leader like hVIVO. Quotient has developed what we believe is a gold standard antibody microarray to help combat the COVID-19 pandemic. This collaboration is uniquely positioned to leverage our combined expertise and help address the large need for antibody testing in the U.K. and beyond,” said Franz Walt, Chief Executive Officer of Quotient.
The MosaiQ COVID-19 Antibody Microarray was CE marked (certified to meet EU requirements) as of May 1, 2020 based on testing that demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies). The test is designed as a serological disease screen specific to COVID-19. It detects the IgG and IgM antibodies that humans develop when infected by SARS-CoV-2.
About hVIVO, part of Open Orphan plc
Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of Covid-19 in 2020. The Company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models.
|
|
|
Post by JHam on May 11, 2020 7:46:11 GMT
$ORPH's stock (Open Orphan, hVIVO's parent company) is up almost 30% in London at the moment on this news. Now that a major service company like hVIVO has partnered up with Quotient in London, I imagine others around Europe will follow.
|
|
|
Post by magnus123 on May 11, 2020 21:34:47 GMT
Good news and nice day. It's encouraging to see that QTNT is finally not losing all gains after news. I don't believe that the deal with hvivo is that big, but it clearly shows the ability of Walt to execute on the commercial shows. And that is so important.
The biggest gift would be definitely the biggest catalyst now, although the demand in the EU alone should be big enough to sell all machines out. We will see.
It seems like our additional buying in the mid 8s was the right decision, Jham.
|
|
|
Post by JHam on May 12, 2020 2:15:17 GMT
Good news and nice day. It's encouraging to see that QTNT is finally not losing all gains after news. I don't believe that the deal with hvivo is that big, but it clearly shows the ability of Walt to execute on the commercial shows. And that is so important. The biggest gift would be definitely the biggest catalyst now, although the demand in the EU alone should be big enough to sell all machines out. We will see. It seems like our additional buying in the mid 8s was the right decision, Jham. It’s big news in that a leading service company went all in with QTNT, thus validating the test. Others will surely follow, but the biggest news will be FDA EUA approval. In ordinary times I think this news would stick and the pps would form a new base. No one wants to sit and hold though right now. They’re in and out, onto the next corona pump. Sad, but that’s where we’re at. If one plays it right though, it’s possible to make money. My prediction is that with FDA news, this will pop to $10 or $11 premarket, then right back down to $8/7. I think QTNT is going to pay great rewards for shareholders as we get closer to next year when their base business starts to crank up and coronavirus is (hopefully) behind us.
|
|
|
Post by magnus123 on May 13, 2020 13:10:41 GMT
Franz Walt InterviewVery interesting interview from early April. Don't know if this has been already posted here.
|
|
|
Post by JHam on May 13, 2020 13:53:15 GMT
Franz Walt InterviewVery interesting interview from early April. Don't know if this has been already posted here. Yeah I posted back on the first page, but it’s worthy of a second post.
|
|
|
Post by vzveteran on May 13, 2020 16:03:22 GMT
Is anyone buying at these levels?
|
|
|
Post by magnus123 on May 13, 2020 16:50:44 GMT
Is anyone buying at these levels? I was too late. Still have a buy order at 6.90.
|
|
|
Post by magnus123 on May 13, 2020 17:17:23 GMT
I got the notification that the Abbott test produces false results. Should be good for QTNT. The FDA should approve our Test immediately.
|
|
|
Post by selluwud on May 13, 2020 18:33:27 GMT
Timing here is paradoxical, waiting for an overall market crash sucking all but a few avante garde COVID issues down to catch a price as close to the bottom as possible or missing the boat because of COVID testing related news that explodes the stock upward. What to do?? I'm sitting tight at a higher price than current on the belief FDA approval with ramped up testing are in the near future. I have more $$ exposed here than I should anyway.
|
|
|
Post by JHam on May 13, 2020 18:37:37 GMT
I got the notification that the Abbott test produces false results. Should be good for QTNT. The FDA should approve our Test immediately. I saw this news too. Sucks for COVID response, but good for QTNT. FDA approval can’t come fast enough. Still thinking early next week, but would love to see it happen in the next two days. And I hope they promote the crap out of it.
|
|